{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T11:40:31Z","timestamp":1768736431696,"version":"3.49.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Genetics and Metabolism"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.ymgme.2024.108494","type":"journal-article","created":{"date-parts":[[2024,5,15]],"date-time":"2024-05-15T06:31:37Z","timestamp":1715754697000},"page":"108494","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Usefulness of antibody-drug conjugate as preconditioning for hematopoietic stem cell-targeted gene therapy in wild-type and Fabry disease mouse models"],"prefix":"10.1016","volume":"142","author":[{"given":"Jin","family":"Ogata","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yohta","family":"Shimada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toya","family":"Ohashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymgme.2024.108494_bb0005","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1056\/NEJM196705252762101","article-title":"Enzymatic defect in Fabry's disease. Ceramidetrihexosidase deficiency","volume":"276","author":"Brady","year":"1967","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymgme.2024.108494_bb0010","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa1510198","article-title":"Treatment of Fabry\u2019s disease with the pharmacologic chaperone Migalastat","volume":"375","author":"Germain","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymgme.2024.108494_bb0015","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1136\/jmedgenet-2016-104178","article-title":"Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study","volume":"54","author":"Hughes","year":"2017","journal-title":"J.Med.Genet."},{"key":"10.1016\/j.ymgme.2024.108494_bb0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymgme.2022.11.002","article-title":"Venglustat, an orally administered glucosylceramide synthase inhibitor: assessment over 3 years in adult males with classic Fabry disease in an open-label phase 2 study and its extension study","volume":"138","author":"Deegan","year":"2023","journal-title":"Mol.Genet.Metab."},{"key":"10.1016\/j.ymgme.2024.108494_bb0025","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1038\/s41467-021-21371-5","article-title":"Lentivirus-mediated gene therapy for Fabry disease","volume":"12","author":"Khan","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymgme.2024.108494_bb0030","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.ymgme.2007.06.013","article-title":"Influence of antibody formation on reduction of globotriaosylceramide (GL-3) in urine from Fabry patients during agalsidase beta therapy","volume":"92","author":"Ohashi","year":"2007","journal-title":"Mol.Genet.Metab."},{"key":"10.1016\/j.ymgme.2024.108494_bb0035","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.ymgme.2008.03.008","article-title":"Reduced alpha-Gal a enzyme activity in Fabry fibroblast cells and Fabry mice tissues induced by serum from antibody positive patients with Fabry disease","volume":"94","author":"Ohashi","year":"2008","journal-title":"Mol.Genet.Metab."},{"key":"10.1016\/j.ymgme.2024.108494_bb0040","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1681\/ASN.2018030329","article-title":"Effects of enzyme replacement therapy and antidrug antibodies in patients with Fabry disease","volume":"29","author":"Lenders","year":"2018","journal-title":"J.Am.Soc.Nephrol."},{"key":"10.1016\/j.ymgme.2024.108494_bb0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymgme.2022.106981","article-title":"Patient reported quality of life and medication adherence in Fabry disease patients treated with migalastat: a prospective, multicenter study","volume":"138","author":"M\u00fcntze","year":"2023","journal-title":"Mol.Genet.Metab."},{"key":"10.1016\/j.ymgme.2024.108494_bb0050","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1038\/s10038-019-0599-z","article-title":"Mutation spectrum of alpha-galactosidase gene in Japanese patients with Fabry disease","volume":"64","author":"Kobayashi","year":"2019","journal-title":"J.Hum.Genet."},{"key":"10.1016\/j.ymgme.2024.108494_bb0055","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24065579","article-title":"Prevalence of neutralizing antibodies against adeno-associated virus serotypes 1, 2, and 9 in non-injected Latin American patients with heart failure-ANVIAS study","volume":"24","author":"Sierra-Delgado","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ymgme.2024.108494_bb0060","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1002\/jmv.23818","article-title":"The prevalence of neutralizing antibodies against adeno-associated virus capsids is reduced in young Japanese individuals","volume":"86","author":"Mimuro","year":"2014","journal-title":"J.Med.Virol."},{"key":"10.1016\/j.ymgme.2024.108494_bb0065","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.omtm.2022.10.014","article-title":"The seroprevalence of neutralizing antibodies against the adeno-associated virus capsids in Japanese hemophiliacs","volume":"27","author":"Kashiwakura","year":"2022","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymgme.2024.108494_bb0070","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.ymthe.2020.12.007","article-title":"Current clinical applications of in vivo gene therapy with AAVs","volume":"29","author":"Mendell","year":"2021","journal-title":"Mol.Ther."},{"key":"10.1016\/j.ymgme.2024.108494_bb0075","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.975803","article-title":"Immunogenicity and toxicity of AAV gene therapy","volume":"13","author":"Ertl","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymgme.2024.108494_bb0080","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/S0140-6736(21)02017-1","article-title":"Lentiviral haematopoietic stem-cell gene therapy for early-onset metachromatic leukodystrophy: long-term results from a non-randomised, open-label, phase 1\/2 trial and expanded access","volume":"399","author":"Fumagalli","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.ymgme.2024.108494_bb0085","doi-asserted-by":"crossref","first-page":"55","DOI":"10.15690\/vramn.v67i10.417","article-title":"Safety of retroviral vectors in gene therapy","volume":"10","author":"Bogoslovskaia","year":"2012","journal-title":"Vestn.Ross.Akad.Med.Nauk."},{"key":"10.1016\/j.ymgme.2024.108494_bb0090","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1517\/14712598.2011.562496","article-title":"Genotoxicity of retroviral hematopoietic stem cell gene therapy","volume":"11","author":"Trobridge","year":"2011","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.ymgme.2024.108494_bb0095","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1080\/14712598.2022.2124857","article-title":"Treatment of cerebral adrenoleukodystrophy: allogeneic transplantation and lentiviral gene therapy","volume":"22","author":"Gupta","year":"2022","journal-title":"Expert. Opin. Biol. Ther."},{"key":"10.1016\/j.ymgme.2024.108494_bb0100","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1056\/NEJMoa2109167","article-title":"Acute myeloid leukemia case after gene therapy for sickle cell disease","volume":"386","author":"Goyal","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymgme.2024.108494_bb0105","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.936985","article-title":"Clinical study of total bone marrow combined with total lymphatic irradiation pretreatment based on tomotherapy in hematopoietic stem cell transplantation of acute leukemia","volume":"12","author":"Kong","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ymgme.2024.108494_bb0110","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1038\/s41467-018-08201-x","article-title":"Selective hematopoietic stem cell ablation using CD117-antibody-drug-conjugates enables safe and effective transplantation with immunity preservation","volume":"10","author":"Czechowicz","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymgme.2024.108494_bb0115","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1038\/s41571-023-00776-9","article-title":"Mitigating long-term and delayed adverse events associated with cancer treatment: implications for survivorship","volume":"20","author":"Lustberg","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.ymgme.2024.108494_bb0120","doi-asserted-by":"crossref","first-page":"2700","DOI":"10.1182\/bloodadvances.2019000516","article-title":"Nongenotoxic antibody-drug conjugate conditioning enables safe and effective platelet gene therapy of hemophilia a mice","volume":"3","author":"Gao","year":"2019","journal-title":"Blood Adv."},{"key":"10.1016\/j.ymgme.2024.108494_bb0125","doi-asserted-by":"crossref","first-page":"1031334","DOI":"10.3389\/fimmu.2022.1031334","article-title":"Antibody based conditioning for allogeneic hematopoietic stem cell transplantation","volume":"13","author":"Saha","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymgme.2024.108494_bb0130","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1038\/nbt.3584","article-title":"Non-genotoxic conditioning for hematopoietic stem cell transplantation using a hematopoietic-cell-specific internalizing immunotoxin","volume":"34","author":"Palchaudhuri","year":"2016","journal-title":"Nat.Biotechnol."},{"key":"10.1016\/j.ymgme.2024.108494_bb0135","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1182\/blood.2021012366","article-title":"A CD45-targeted antibody-drug conjugate successfully conditions for allogeneic hematopoietic stem cell transplantation in mice","volume":"139","author":"Saha","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.ymgme.2024.108494_bb0140","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.jaci.2020.04.033","article-title":"Efficacy and safety of anti-CD45-saporin as conditioning agent for RAG deficiency","volume":"147","author":"Castiello","year":"2021","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.ymgme.2024.108494_bb0145","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1038\/s41467-018-08202-w","article-title":"Hematopoietic chimerism and donor-specific skin allograft tolerance after non-genotoxic CD117 antibody-drug-conjugate conditioning in MHC-mismatched allotransplantation","volume":"10","author":"Li","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymgme.2024.108494_bb0150","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.omtm.2020.02.001","article-title":"Effective multi-lineage engraftment in a mouse model of Fanconi Anemia using non-genotoxic antibody-based conditioning","volume":"17","author":"Srikanthan","year":"2020","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymgme.2024.108494_bb0155","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1038\/s41434-022-00357-y","article-title":"A novel preclinical model of mucopolysaccharidosis type II for developing human hematopoietic stem cell gene therapy","volume":"30","author":"Shimada","year":"2023","journal-title":"Gene Ther."},{"key":"10.1016\/j.ymgme.2024.108494_bb0160","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1089\/hum.2014.158","article-title":"Hematopoietic stem cell gene therapy corrects neuropathic phenotype in murine model of Mucopolysaccharidosis type II","volume":"26","author":"Wakabayashi","year":"2015","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymgme.2024.108494_bb0165","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.omtm.2020.09.012","article-title":"Ex vivo gene therapy treats bone complications of Mucopolysaccharidosis type II mouse models through bone remodeling reactivation","volume":"19","author":"Wada","year":"2020","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymgme.2024.108494_bb0170","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.ymgme.2020.06.007","article-title":"Efficient engraftment of genetically modified cells is necessary to ameliorate central nervous system involvement of murine model of mucopolysaccharidosis type II by hematopoietic stem cell targeted gene therapy","volume":"130","author":"Miwa","year":"2020","journal-title":"Mol.Genet.Metab."},{"key":"10.1016\/j.ymgme.2024.108494_bb0175","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1002\/jgm.1566","article-title":"Minimum requirement of donor cells to reduce the glycolipid storage following bone marrow transplantation in a murine model of Fabry disease","volume":"13","author":"Yokoi","year":"2011","journal-title":"J. Gene Med."},{"key":"10.1016\/j.ymgme.2024.108494_bb0180","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.ymgme.2005.01.007","article-title":"Non-invasive screening method for Fabry disease by measuring globotriaosylceramide in whole urine samples using tandem mass spectrometry","volume":"85","author":"Kitagawa","year":"2005","journal-title":"Mol.Genet.Metab."},{"key":"10.1016\/j.ymgme.2024.108494_bb0185","doi-asserted-by":"crossref","DOI":"10.1172\/JCI145501","article-title":"Antibody-drug conjugates plus Janus kinase inhibitors enable MHC-mismatched allogeneic hematopoietic stem cell transplantation","volume":"131","author":"Persaud","year":"2021","journal-title":"J.Clin.Invest."},{"key":"10.1016\/j.ymgme.2024.108494_bb0190","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.omtm.2021.04.016","article-title":"Non-genotoxic conditioning facilitates hematopoietic stem cell gene therapy for hemophilia a using bioengineered factor VIII","volume":"21","author":"Russell","year":"2021","journal-title":"Mol. Ther. Methods Clin. Dev."}],"container-title":["Molecular Genetics and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719224003780?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719224003780?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,10]],"date-time":"2024-07-10T11:39:35Z","timestamp":1720611575000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1096719224003780"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":38,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["S1096719224003780"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgme.2024.108494","relation":{},"ISSN":["1096-7192"],"issn-type":[{"value":"1096-7192","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Usefulness of antibody-drug conjugate as preconditioning for hematopoietic stem cell-targeted gene therapy in wild-type and Fabry disease mouse models","name":"articletitle","label":"Article Title"},{"value":"Molecular Genetics and Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymgme.2024.108494","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"108494"}}